Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
As a leading provider of Chimeric antigen receptors (CARs) products, Creative Biolabs provides unparalleled CellRapeutics™ third generation CARs design to satisfy various customers' needs. We completely understand the challenge in constructing CARs. Thankfully, with an excellent and efficient team, and advanced techniques, we have successfully built up an solid platform for CARs construction.
Fig.1 The generations of chimeric antigen receptors (CAR).1
Generally, the third generation CARs consist of an antigen binding unit, a spacer, a transmembrane domain and endodamain(s) the same as first or second-generations. The difference between the third generation and other generations is the co-stimulatory signaling domain, which composed of two different co-stimulatory signaling units in the intracellular regions besides the CD3ζ or FcεRIγ signaling domain. The major advantage of the third generation CARs is that it can induce high level cytokine secretion and significantly increase proliferation speed and survival rate of engrafted T cells. Our skilled scientists have constructed a variety of chimeric antigen receptors with signaling components such as CD28, CD137 (4-1BB), CD134 (OX40) and DAP10.
Creative Biolabs has established and developed world-renowned platform for CAR design, which can provide a superb service for every customer. With the solid reputation as a best-class services provider, we guarantee that CARs products from Creative Biolabs can greatly accelerate your project.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
